Introduction to Biological Therapy in India

Moderate-to-severe plaque psoriasis remains a significant clinical challenge for dermatologists across India, often requiring more than just topical interventions or conventional systemic agents. Over the past decade, the landscape of psoriasis management has shifted dramatically with the introduction of biological therapies. These agents, specifically those targeting the interleukin (IL)-12 and IL-23 pathways like ustekinumab, have revolutionized patient outcomes by providing high rates of skin clearance. However, the high cost of reference biologics has historically limited their accessibility for a large portion of the Indian population. Consequently, the emergence of ustekinumab biosimilars psoriasis treatments offers a promising avenue to enhance affordability and patient reach. This transition toward biosimilars necessitates a rigorous evaluation of their therapeutic equivalence to ensure that clinical efficacy and safety are not compromised in the pursuit of cost-effectiveness.

The Expanding Role of Ustekinumab Biosimilars Psoriasis Care

Biosimilars are highly similar versions of an approved biological medicine, with no clinically meaningful differences in terms of safety, purity, or potency. In the context of ustekinumab biosimilars psoriasis therapy, these agents target the p40 subunit common to both IL-12 and IL-23 cytokines, which play pivotal roles in the inflammatory cascade of psoriasis. As patents for the reference product expire, multiple global and Indian pharmaceutical companies have developed biosimilar candidates. These products undergo an extensive "totality of evidence" assessment, which includes analytical, non-clinical, and clinical comparative studies. The recent systematic review and meta-analysis published in 2026 provide much-needed pooled data to validate whether these biosimilars achieve the same benchmarks as the originator during the initial, critical phase of treatment. For clinicians in India, where the biologic market is rapidly expanding, such data is vital for making evidence-based prescribing decisions that balance efficacy with the economic realities of their patients. Furthermore, understanding the pre-switch performance of these drugs allows for a smoother integration into standard dermatological practice, ensuring that patients receive the highest standard of care without unnecessary financial burden.

Evaluating Therapeutic Equivalence Through Meta-Analysis

The recent meta-analysis included nine randomized clinical trials encompassing over 4,500 participants, specifically focusing on the therapeutic equivalence of ustekinumab biosimilars compared to the reference product. The primary endpoint analyzed was the 75% improvement in the Psoriasis Area and Severity Index (PASI 75) at week 12. This timeframe is considered the gold standard for assessing early treatment response in plaque psoriasis. The study utilized a prespecified equivalence margin of ± 10%, a stringent criterion used by regulatory bodies like the FDA and EMA. The pooled risk difference for PASI 75 was found to be 0.02, which comfortably falls within the equivalence margin. Moreover, the researchers observed very low heterogeneity between the different trials, suggesting that the results are consistent across various biosimilar candidates and study populations. This finding is particularly important because it demonstrates that the clinical performance of these biosimilars is predictable. Additionally, higher benchmarks of skin clearance, such as PASI 90 and PASI 100, also showed equivalence-consistent estimates. This indicates that patients can expect the same high levels of skin clearance regardless of whether they are treated with the biosimilar or the reference biologic during the initial treatment phase.

Safety and Immunogenicity Profiles in the Pre-Switch Period

Safety is a paramount concern when introducing biosimilars into clinical practice. The meta-analysis carefully evaluated treatment-emergent adverse events (TEAEs) through week 28. The results showed a risk difference of only 0.01 between the biosimilar and reference arms, indicating that the safety profiles are essentially identical in the short term. One interesting finding in the study was the lower detection of anti-drug antibodies (ADAs) in the biosimilar arms at week 12. While this might initially seem like an advantage, the authors cautioned that it might reflect variability in the assays used across different trials rather than a clinically significant difference in immunogenicity. Nevertheless, the overall data suggests that biosimilars do not pose an increased risk of adverse reactions or loss of efficacy due to immune responses during the initial therapy window. For Indian practitioners, this is reassuring, as concerns about immunogenicity often deter the use of follow-on biologics. Therefore, the evidence supports the conclusion that ustekinumab biosimilars psoriasis options are as safe as the reference drug, providing a solid foundation for their use as first-line biological options in suitable patients.

Clinical Reassurance for Indian Dermatologists and Patients

The implications of this meta-analysis for the Indian healthcare context are profound. In India, many patients pay out-of-pocket for their medications, making the cost of biologics a major barrier to treatment adherence and initiation. The proven therapeutic equivalence of ustekinumab biosimilars means that dermatologists can confidently recommend these more affordable options. This confidence is backed by rigorous statistical evidence rather than just manufacturer claims. Specifically, the data on PASI 75, 90, and 100 ensures that the therapeutic goals of nearly complete to complete skin clearance are achievable with biosimilars. Moreover, the reassurance provided by this pooled evidence can help in shared decision-making with patients who may be skeptical about the efficacy of a "cheaper" alternative. When clinicians can show that multiple large-scale trials have found no material difference in clinical response or patient-reported quality of life, it enhances trust in the treatment plan. Consequently, the adoption of biosimilars can lead to better long-term management of psoriasis, reducing the systemic complications associated with untreated or undertreated disease.

Navigating Regulatory Pathways and Accessibility in India

The regulatory environment in India, governed by the Central Drugs Standard Control Organization (CDSCO), has evolved to facilitate the entry of "similar biologics" into the market. Indian manufacturers like Biocon and Dr. Reddy's are at the forefront of this movement, bringing ustekinumab biosimilars to the local and global markets. These domestic options are often priced significantly lower than imported reference products, which is a game-changer for the Indian patient population. However, it is essential for clinicians to distinguish between true biosimilars that have undergone rigorous equivalence testing and "biomimics" that may not have the same level of data. The systematic review discussed here focuses on phase III trials that adhere to international standards, providing a benchmark for what clinicians should look for in a biosimilar product. By staying informed about these high-quality meta-analyses, Indian doctors can navigate the complex marketplace more effectively. Furthermore, as more ustekinumab biosimilars enter the market, competition is likely to drive prices down even further, making biological therapy a realistic option for a much larger demographic of psoriasis patients across the country.

Conclusion and Future Directions in Biologic Therapy

In conclusion, the therapeutic equivalence of ustekinumab biosimilars psoriasis treatments is now supported by robust meta-analytic evidence. These findings provide a clear mandate for the use of biosimilars in the management of moderate-to-severe plaque psoriasis, offering the same clinical benefits as the reference product at a potentially lower cost. As we move forward, longer-term data and real-world evidence from switching studies will continue to build on this foundation. For now, the pre-switch data offers immediate reassurance for the initiation of therapy. Clinicians should continue to monitor their patients closely, but the standard of care is clearly shifting toward a more inclusive and affordable biological landscape. By embracing these advancements, the dermatological community in India can significantly improve the lives of those suffering from the burden of chronic plaque psoriasis.

Frequently Asked Questions

What does the term "pre-switch period" mean in the context of this study?

The pre-switch period refers to the initial phase of a clinical trial where patients are randomized to receive either a biosimilar or the reference biologic. This period occurs before any protocol-defined switching of patients from the reference drug to the biosimilar happens. Evaluating this window is critical because it allows researchers to compare the two drugs directly without the confounding variables introduced by the act of switching itself, ensuring a pure comparison of therapeutic equivalence.

Are ustekinumab biosimilars exactly the same as the original reference drug?

Ustekinumab biosimilars are not exact replicas in the way that generic small-molecule drugs are, because biological products are made in living cells and have inherent complexity. However, they are "highly similar," meaning there are no clinically meaningful differences in their safety, purity, or potency. The meta-analysis confirms that they achieve the same clinical outcomes, such as PASI 75 and safety benchmarks, making them therapeutically equivalent for treating moderate-to-severe plaque psoriasis in adult patients.

How do PASI 75, 90, and 100 scores help in assessing psoriasis treatment?

The Psoriasis Area and Severity Index (PASI) is a tool used to measure the severity and extent of psoriasis. A PASI 75 score indicates a 75% reduction in the baseline disease severity, which is a traditional benchmark for treatment success. PASI 90 and PASI 100 represent 90% and 100% clearance, respectively. These higher scores are increasingly targeted in modern clinical practice as they represent near-total or total skin clearance, significantly improving the patient's quality of life and psychological well-being.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of a physician or other qualified health provider with any questions regarding a medical condition. The use of specific medications should be based on a thorough clinical evaluation and shared decision-making between the healthcare provider and the patient. Refer to the latest local and national guidelines for clinical practice.

References

Montes-de-Oca-Saucedo CR et al. Ustekinumab Biosimilars versus Reference Ustekinumab for Moderate-to-Severe Plaque Psoriasis: A Pre-switch Systematic Review and Meta-analysis. BioDrugs. 2026 Jul 02. doi: 10.1007/s40259-026-00795-9. PMID: 42393486.

Indian Journal of Dermatology, Venereology and Leprology. Guidelines for the management of psoriasis in India. 2022.

Central Drugs Standard Control Organization (CDSCO). Guidelines on Similar Biologics: Regulatory Requirements for Marketing Authorization in India. 2016.

World Health Organization. Questions and Answers on Biosimilar Biological Products. 2023.